Covid-19: What is the evidence for the antiviral molnupiravir?
Covid-19: What is the evidence for the antiviral molnupiravir? – The BMJ
The post Covid-19: What is the evidence for the antiviral molnupiravir? appeared first on Links Medicus.
A nationwide observational analysis in Israel showed a fourth dose of the Pfizer vaccine may reduce the short-term risk of Covid-19–related outcomes.
Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting – New England Journal of Medicine Editorial: Covid-19 Boosters — Where from Here? Related: COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines. Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection […]
The post A nationwide observational analysis in Israel showed a fourth dose of the Pfizer vaccine may reduce the short-term risk of Covid-19–related outcomes. appeared first on Links Medicus.
Drug resistant TB – latest developments in epidemiology, diagnostics and management.
Drug resistant TB – latest developments in epidemiology, diagnostics and management – International Journal of Infectious Diseases Related: Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update. WHO Consolidated Guidelines on Drug-resistant Tuberculosis Treatment Randomized Trial: 9-month Treatment for Multi-drug Resistant TB is as Effective as 24-month Treatment Canadian Tuberculosis Standards – […]
The post Drug resistant TB – latest developments in epidemiology, diagnostics and management. appeared first on Links Medicus.
Review: Diagnosis and treatment of pulmonary arterial hypertension.
Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review – JAMA (free for a limited period) Audio Clinical Review: Diagnosis and Treatment of Pulmonary Arterial Hypertension – JAMA Commentary on Twitter This review summarizes current evidence regarding diagnosis and treatment of pulmonary arterial #hypertension. https://t.co/Ebo33PD8Qq — JAMA (@JAMA_current) April 12, 2022
The post Review: Diagnosis and treatment of pulmonary arterial hypertension. appeared first on Links Medicus.
More data suggests the Omicron variant causes milder disease compared to the Delta variant.
Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study – The Lancet Commentary: Covid-19: Symptomatic infection with omicron variant is milder and shorter than with delta, study reports – The BMJ Related: Another study […]
The post More data suggests the Omicron variant causes milder disease compared to the Delta variant. appeared first on Links Medicus.
RCT: Prophylactic Penehyclidine inhalation for prevention of postoperative pulmonary complications in high-risk patients.
Prophylactic Penehyclidine Inhalation for Prevention of Postoperative Pulmonary Complications in High-risk Patients: A Double-blind Randomized Trial – Anesthesiology
The post RCT: Prophylactic Penehyclidine inhalation for prevention of postoperative pulmonary complications in high-risk patients. appeared first on Links Medicus.
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment.
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment – ESMO Open
The post Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. appeared first on Links Medicus.
Review: Drug-induced interstitial lung disease.
Drug-induced interstitial lung disease – European Respiratory Review Related: Systematic Review: Drug-Induced Interstitial Lung Disease
The post Review: Drug-induced interstitial lung disease. appeared first on Links Medicus.
Empyema: ED presentation, evaluation, and management.
Empyema: ED Presentation, Evaluation, and Management – emDocs
The post Empyema: ED presentation, evaluation, and management. appeared first on Links Medicus.
RCT: Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough.
Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials – The Lancet (link to abstract – $ for full-text) Commentary on Twitter For refractory chronic cough or unexplained chronic cough, gefapixant 45 mg twice […]
The post RCT: Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough. appeared first on Links Medicus.